Immunocore identifies new lead compound

The Oxford, UK oncology company Immunocore Ltd has identified a lead compound in its second discovery collaboration with GlaxoSmithKline Plc which is expected to have potential for treating triple negative breast cancers, oesophageal, gastric and ovarian cancers.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom